Akrevia Therapeutic, a Cambridge, MA-based biotech startup focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics has raised $30 million in funding led by F-Prime Capital Partners and Atlas Venture. The funding will be used to accelerate Akrevia's pipeline and proprietary Aklusion® platform, which allows therapeutic antibodies, cytokines and chemokines to be specifically activated in the tumor microenvironment and tailored with precisely optimized pharmacologic
Read More